OncoMax has become a resident of the Skolkovo Foundation

Biotechnological company OncoMax, the first project, jointly financed by Maxwell Biotech Venture Fund and RVC Seed Fund, has acquired the status of a participant of the Center for Elaboration and Commercialization of New Technologies of the Skolkovo Foundation. This decision was made at the meeting of the Expert Collegium of the Foundation, which took place in mid April.

OncoMax, Ltd is a Russian innovation company included in Maxwell Biotech Group Biotechnological Holding. The main activity of OncoMax is directed at the development and introduction the Russian market of the innovative biopharmaceutical medicines for diagnostics and treatment of oncological diseases. The project of OncoMax has won many Russian and foreign awards, such as AACR-AstraZeneca Award, ‘For the best Russian innovation project in medicine among young scientists’ and the ‘Golden Hundred of the Zvorykino Project’.

According to Dmitry Popov, Managing Partner of Maxwell Biotech Group, "the acquisition of the status of a company-resident of Skolkovo by OncoMax confirms a serious scientific and technological basis and high marketing potential of the drug developed by the company. It is also encouraging that OncoMax is a project, based on the results of the work of a team of young Russian scientists. We are optimistic about the future cooperation of our portfolio companies and Skolkovo Foundation."

“We see in practice the evidence of synergy between Skolkovo and RVC represented by the Seed Fund, when projects with global prospects find the approval of both investors and the widest range of international experts. We see that one of the key objectives of the fund’s work is the further integration with Skolkovo Foundation”, - Alexey Teleshev, director of RVC Seed Fund, noted.

The first product of the company, ОМ-RCA-01, is intended for a target therapy of the renal cell carcinoma and in the future this drug can be also used for treating lung cancer. The drug purposefully blocks a specific target on a tumour cell, thus affecting the mechanisms of tumor development and resistance. The drug can be prescribed both as first-line treatment and in case of inefficiency of other types of therapy in the second and subsequent lines.

In November 2010, the company successfully completed a stage of the humanization of the projected drug. The obtained antibody showed high specificity and affinity to the target antigen (both used during the immunization and commercial), and at the same time these indicators were higher than those of the most commercially successful target drug for the treatment of oncologic diseases such as Avastin (Bevacizumab). Currently the drug is undergoing the stage of pre-clinical trials.

 

Анна Зеленкова,
PR директор, ООО «Максвелл Биотех Групп»;
Тел: +7 (495) 411-6992
E-mail: zelenkova@maxwellbiotech.ru